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Abstract
Introduction: Patients undergoing mechanical ventilation (MV) are frequently administered prolonged and/or high
doses of opioids which when removed can cause a withdrawal syndrome and difficulty in weaning from MV. We
tested the hypothesis that the introduction of enteral methadone during weaning from sedation and analgesia in
critically ill adult patients on MV would decrease the weaning time from MV.
Methods: A double-blind randomized controlled trial was conducted in the adult intensive care units (ICUs) of four
general hospitals in Brazil. The 75 patients, who met the criteria for weaning from MV and had been using fentanyl
for more than five consecutive days, were randomized to the methadone (MG) or control group (CG). Within the
first 24 hours after study enrollment, both groups received 80% of the original dose of fentanyl, the MG received
enteral methadone and the CG received an enteral placebo. After the first 24 hours, the MG received an
intravenous (IV) saline solution (placebo), while the CG received IV fentanyl. For both groups, the IV solution was
reduced by 20% every 24 hours. The groups were compared by evaluating the MV weaning time and the duration
of MV, as well as the ICU stay and the hospital stay.
Results: Of the 75 patients randomized, seven were excluded and 68 were analyzed: 37 from the MG and 31 from
the CG. There was a higher probability of early extubation in the MG, but the difference was not significant (hazard
ratio: 1.52 (95% confidence interval (CI) 0.87 to 2.64; P = 0.11). The probability of successful weaning by the fifth
day was significantly higher in the MG (hazard ratio: 2.64 (95% CI: 1.22 to 5.69; P < 0.02). Among the 54 patients
who were successfully weaned (29 from the MG and 25 from the CG), the MV weaning time was significantly
lower in the MG (hazard ratio: 2.06; 95% CI 1.17 to 3.63; P < 0.004).
Conclusions: The introduction of enteral methadone during weaning from sedation and analgesia in mechanically
ventilated patients resulted in a decrease in the weaning time from MV.
Introduction
Critically ill patients are often subjected to procedures
that cause pain and anxiety [1,2]. These procedures may
also result in the increased activity of endogenous cate-
cholamines, higher global and myocardial oxygen con-
sumption, hypercoagulability and immunosuppression
[3]. The use of potent analgesics, such as opioids, pro-
vides comfort and facilitates adaptation to mechanical
ventilation (MV) [4,5].
Fentanyl is the preferred opioid used in many ICUs
[6,7] due to its potency and its non-induction of hista-
mine release, resulting in a low risk of inducing hemo-
dynamic instability. However, the short duration of
action of this medication often requires a continuous
infusion, resulting in a rapid induction of tolerance,
dependence and withdrawal syndrome possibly resulting
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in psychomotor agitation and/or patient-ventilator asyn-
chrony [8-10]. The combination of midazolam and fen-
tanyl in continuous infusion is the protocol used in
most Brazilian ICUs. [7] The use of continuous infusion
sedation is associated with prolongation of mechanical
ventilation, longer ICU stays and longer hospital stays
[11].
Several alternative treatments have emerged in the
past few years that aim to reduce the duration of MV
[12-15]. However, the use of opioids and benzodiaze-
pines remains necessary in several situations, such as
acute respiratory distress syndrome, intracranial hyper-
tension or hemodynamic instability. In these situations
high doses are often used for long periods, increasing
the risk of acute withdrawal syndrome [8-10]. Several
strategies to manage withdrawal have been utilized,
including gradual weaning, replacement by another
long-acting opioid, the use of opioid antagonists and the
administration of adrenergic agonists, such as clonidine
[16-20].
The introduction of long-acting opioids by enteral
administration to prevent opioid withdrawal syndrome
was first described in 1965 with the use of methadone
for the rehabilitation of heroin users. Methadone
reduces the drug withdrawal syndrome and thus helps
to prevent relapse [21]. Since the 1970s, methadone has
been used in programs regulated by the US government
for the treatment of opioid dependency [22].
Several studies have demonstrated the efficacy and
safety of methadone use to prevent and/or treat the
withdrawal syndrome related to opioid use in pediatric
ICUs [23-27]. However, there have been no similar stu-
dies conducted in adult ICUs.
The aim of this study was to test the hypothesis that
the introduction of enteral methadone during weaning
from sedation and analgesia in critically ill adult patients
would decrease the time of weaning from MV.
Materials and methods
A prospective, controlled, randomized, double-blind
clinical trial was conducted between April 2005 and
October 2009 in the adult ICUs of four general hospitals
in southern Brazil.
Participants
The subjects studied were severely ill patients who
required MV and the continuous use of fentanyl and
who met the following inclusion criteria: MV for at least
five days, the use of fentanyl analgesia in varying doses
for at least five days, or a dose of fentanyl ≥ 5 μg/kg/
hour for at least 12 hours [9,26]. Subjects were also
required to meet the following ventilation weaning cri-
teria: reversal of the process that caused the respiratory
failure, adequate oxygenation (PaO2/FiO2 > 200; positive
end-expiratory pressure (PEEP) ≤ 5; FiO2 ≤ 0.4 and pH
≥7.25), hemodynamic stability (with minimal or no
vasoactive drugs) and neurological stability (ability to
initiate respiratory effort) [28]. We excluded patients
younger than 18 years, those with terminal diseases and
those with cervical spinal cord injuries or neuromuscu-
lar diseases.
Patients were included in the study only after
informed consent, documented as the regulations pro-
vided for in Resolution 196, October 1996, the National
Board of Health. The study protocol and consent to par-
ticipate in the study and consent to publish were
approved by the Research Ethics Committee of Hospital
Municipal São José of Joinville (Committee referenced
by the other participating institutions), and recorded on
15 October 2004 under number 008/2004.
Patients were followed up from the time they met the
inclusion criteria and agreed to participate in the study
until death or hospital discharge.
Interventions
The enrolled patients were randomized into two groups:
the methadone group (MG), for whom intravenous fen-
tanyl was replaced with enteral methadone; and the con-
trol group (CG), who underwent a gradual reduction of
intravenous fentanyl.
The MG received the following treatment:
1. One capsule of methadone (10 mg) was adminis-
tered enterally every six hours.
2. The rate of fentanyl infusion was reduced by 20%
[16].
3. After 24 hours, the vial of fentanyl infusion was
replaced by the study. solution (placebo) and the
infusion rate was reduced by 20% [16].
4. The infusion rate for the placebo solution was
reduced by 20% every 24 hours [16].
The following schedule was applied for the CG:
1. A placebo capsule was administered enterally
every six hours.
2. The rate of fentanyl infusion was reduced by 20%
[16].
3. After 24 hours, the vial of fentanyl was replaced
by the study solution (fentanyl) and the infusion rate
was reduced by 20% [16].
4. The infusion rate for the fentanyl solution was
reduced by 20% every 24 hours [16].
Occasional episodes of intolerance to opioid withdra-
wal, characterized by agitation, anxiety, tremors,
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myoclonus, vomiting, diarrhea, piloerection, sweating,
dilated pupils, tachycardia and hypertension, were trea-
ted with supplemental opioids as follows:
1. Bolus 1 to 2 μg/kg of fentanyl, maximum of four
times in 24 hours.
2. Increase the capsule dose (methadone/placebo) by
50%.
3. Increase the infusion rate of the solution (fenta-
nyl/placebo) to the previous dose.
The patients received benzodiazepines and antipsycho-
tic agents by physician direction in the ICU. We did not
use standard sedation scales to titrate sedation in the
participant ICUs. However, the sedation goal was to
keep patients calm and awake, or when not possible,
slightly sedated, that is, easily arousable.
The study solutions and capsules were handled, identi-
fied and released by a pharmacist, who was the only
person who knew the nature of the administered drugs.
The capsules contained starch or 10 mg of methadone
and were indistinguishable in appearance. The solutions
contained 100 ml of saline or 50 ml of saline and 50 ml
of fentanyl, also indistinguishable by sight.
We assessed readiness for weaning every morning.
The ability to sustain unassisted breathing was also
assessed every morning by performing a spontaneous
breathing trial in patients with low levels of pressure
support (≤ 10 cmH2O), and with other clinical and
objective signs of stability. Midazolam and fentanyl were
used for sedation and analgesia. Daily interruption of
sedatives was not standardized in the participant ICUs.
We did not have a standardized sedation scale to titrate
sedation, nor did we use a uniform delirium diagnosis
method. In the ICUs in the study using gradual weaning
of sedation, the infusion rate was reduced by 20% every
24 hours. The purpose of this schedule was to prevent
the withdrawal syndrome.
The main outcome variables assessed were the fol-
lowing: duration of ventilation weaning (weaning suc-
cess was defined as 48 hours without reinstitution of
MV) [29], duration of MV, length of ICU stay and
length of hospital stay. The clinical and demographic
data collected included age, sex, weight, indications for
hospitalization, comorbidities (hypertension, diabetes
mellitus, chronic lung disease, psychiatric and neurolo-
gical disorders, obesity, alcoholism, smoking or illicit
drug use), the information necessary to calculate the
APACHE II (Acute Physiology And Chronic Health
Evaluation) score and deaths before and after discharge
from the ICU [30]. We also recorded the following fac-
tors: need for supplemental doses of fentanyl for the
treatment of opioid withdrawal intolerance, accumu-
lated doses of fentanyl and midazolam maleate used
before the start of weaning and the use of other
sedatives.
Randomization
The randomization between the two groups (MG and
CG) was performed by a simple lottery system; 75 pieces
of paper with the word yes and the same number with
the word no were placed in a package. The sequence
was determined by drawing, and was recorded on a spe-
cific form to be used by the pharmacist. Only the phar-
macist from the hospital at which the randomization
process occurred knew the nature of the administered
medications.
Sample size and statistical methods
The sample size was determined as 70 patients, calcu-
lated from data obtained in a pilot study (23 patients)
that preceded this study. For this calculation, the time-
to-event analysis was used, with a cumulative probability
of successful extubation on the fifth day in 20% of the
CG and 50% of the MG. We applied a significance level
of 5% and power of 80%.
For the statistical processing of the data, we used
NCSS Statistical Software 2007, PASS 11 (Power Analy-
sis and Sample Size) and GraphPad Prism 4. Continuous
variables are shown as the means ± standard deviation
and were compared using a Student’s t-test. Categorical
variables are expressed as their absolute and relative
values and were compared using a chi-squared test. A
P-value < 0.05 was considered statistically significant. To
test the effects of two therapeutic regimens on the dura-
tion of weaning, the duration of MV and the length ICU
stay, we used time-to-event analysis. These data were
presented as Kaplan-Meier curves, and for comparison
between groups, a Cox regression (Cox proportional
hazards model) was used. Patients who died were cen-
sored at the time of death. The time of weaning was
also assessed, taking into consideration only the patients
who were permanently disconnected from MV. For
questions inherent to the study methodology, the inter-
ruption of the fentanyl infusion in patients from the CG
occurred only on the fifth day; for this reason, we also
evaluated the weaning period in the interval between
randomization and the fifth day. For the analysis of
MV-free days within 28 days after the start of the proto-
col, the median, interquartile range (IQR) and Wilcoxon
rank-sum (Mann-Whitney test) were used when com-
paring the groups.
Results
Between the months of April 2005 and October 2009,
75 patients were randomized at the four ICUs: 43 to the
MG and 32 to the CG. Of these, seven patients were
excluded (two informed consent withdrawal, one
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suspension of sedation, one hospital transfer, one rando-
mized twice, two clinical worsening) and 68 patients
were included in the analysis: 37 in the MG and 31 in
the CG (Figure 1). The patients were monitored until
discharge or death. All patients were analyzed by the
intention-to-treat method.
Patients in both groups had similar demographic and
clinical characteristics (Table 1).
There were no significant differences between the
groups when we analyzed the weaning time of the 68
patients (Hazard ratio: 1.52; 95% CI: 0.87 to 2.64; P =
0.11). Analyzing the interval between randomization and
the fifth day of weaning, the probability of successful
weaning was significantly higher in the MG (Hazard
ratio: 2.64; 95% CI: 1.22 to 5.69; P < 0.02). The median
weaning time was five days in the MG (95% CI: 2.42 to
7.58), and in the CG, this interval was seven days (95%
CI: 2.87 to 11.13) (Figure 2). Of the 68 patients included
in the analysis (MG: 37 versus CG: 31), 14 died before
completing the ventilation weaning (Table 2). Among
the 54 survivors (MG: 29 versus CG: 25), the time of
MV weaning was significantly lower in the MG (Hazard
ratio: 2.06; 95% CI: 1.17 to 3.63; P < 0.004). The median
weaning time was four days for the MG (95% CI: 1.99
to 6.01) and seven days (95% CI: 2.5 to 11.5) for the CG
(Figure 3).
Analyzing the MV-free days after 28 days from the
beginning of the protocol, we observed a trend favoring
the MG, with a median of 20 days (7 to 24) versus16
days (0 to 22) in the CG (P = 0.13).
There were no significant differences in the total
duration of MV between the groups (hazard ratio 1.54;
95% CI: 0.85 to 2.81; P = 0.14). The median time of
MV in the MG was 15 days (95% CI: 11.03 to 18.97)
and in the CG, this interval was 20 days (95% CI:
15.25 to 24.75). The duration of the ICU stay did not
differ between the groups (hazard ratio 1.47; 95% CI:
0.81 to 2.66, P = 0.19) and was 19 days (95% CI: 14.23
to 23.77) in the MG and 25 days (95% CI: 20.37 to
29.63) in the CG.
The groups also did not differ regarding the length of
hospital stay (hazard ratio 1.14; 95% CI: 0.65 to 2.00, P
= 0.62), with a median of 44 days (95% CI: 33.67 to
54.33) in the MG and 47 days (95% CI: 33.67 to 54.33)
in the CG.
The cumulative dose of fentanyl received before the
start of weaning was similar in both groups (MG: 40,608
± 24,882 versus 41,284 ± 20,545 μg, P = 0.90). In the
MG, 10 patients showed signs of opioid withdrawal
intolerance compared to 12 patients in the CG (P =
0.30). Patients in both groups used other drugs for seda-
tion, analgesia and delirium treatment during the ICU
stay; 29 were from the MG and 27 were from the CG (P
= 0.34).
The groups were also similar with regard to the pre-
sence of comorbidities (P = 0.75), the development of
Randomized (n = 75)
Methadone group (n = 43) Control group (n = 32)
Included in analysis (n = 37) Included in analysis (n = 31)
Excluded (n = 6):
1 informed consent withdrawal
1 suspension of sedation
1 hospital transfer
1 randomized twice
2 clinical worsening
Excluded (n = 1):
1 informed consent withdrawal
Figure 1 Study flowchart.
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complications during the ICU stay (P = 0.85) and the
number of patients undergoing tracheostomy (P = 0.67).
The hospital mortality rate was similar between the
groups (MG: 12/37 versus CG: 12/31, P = 0.58). Of the
24 deaths, 9 occurred after discharge from the ICU.
Among the 15 patients who died during the ICU stay,
14 did not complete MV weaning (MG: 8/27 versus CG:
6/31, P = 0.81).
Discussion
This study compared the effects of a gradual reduction
of intravenous fentanyl versus the replacement of fenta-
nyl by enteral methadone during the weaning from
sedation and analgesia in patients undergoing MV. The
results demonstrated that the substitution of intravenous
fentanyl with enteral methadone shortens the time of
ventilation weaning in critically ill adult patients under-
going prolonged sedation and analgesia.
The overall analysis of the weaning time from MV
showed no differences between the groups analyzed by
this study. However, the chance of successful weaning
by the fifth day was significantly higher in the MG (Fig-
ure 2). This time interval was adopted based on a pilot
study that preceded this study and informed the sample
size calculation. In this calculation, the fifth day after
inclusion in the protocol was identified as the threshold
for ensuring the success of weaning. Rozendaal et al.
used a combination of remifentanyl and propofol to
reduce the time of ventilation weaning and reported
that the effect of this combination on weaning time was
time-dependent, as we observed in the methadone
group [31].
During this five-day period, the CG continued to
receive fentanyl, a situation that may have contributed
to the prolongation of ventilation weaning. The benefit
of this strategy of fentanyl substitution during the wean-
ing period is probably due to the decrease in time
required to remove the intravenous infusion of fentanyl.
In the MG, the complete withdrawal of fentanyl
occurred after 24 hours with all patients. However, in
the CG, the gradual withdrawal of fentanyl resulted in
the persistence of this drug infusion for at least five
days. Thus, it is possible that the action of this potent
opioid may have hindered the final disconnection from
MV in the CG. It is possible that a more aggressive
reduction of fentanyl in the control group, for example
daily fentanyl interruption returning the drug only in
case of signs of opioid withdrawal, might have acceler-
ated weaning in the control group.
By focusing the analysis on the 54 patients who com-
pleted the MV weaning, we observed that the group
receiving enteral methadone as a substitute for fentanyl
benefitted by the reduction in the time of weaning from
MV (Figure 3). However, interpretation of this data
should be very cautious because it is vulnerable to attri-
tion bias: non-weaned patients were excluded, and we
cannot completely reject an association between the
Table 1 Demographic and clinical characteristics.
Characteristics MG
(n = 37)
CG
(n = 31)
P
value
Males, number (%) 27 (72) 26 (83) 0.28
Age 43 ± 18 45 ± 17 0.60
Weight 82 ± 16 84 ± 19 0.58
APACHE II 19 ± 8 18 ± 6 0.59
Cause of hospitalization, n (%)
Trauma 17 (45) 14 (45) 0.94
Respiratory 6 (16) 3 (9) 0.42
Sepsis 5 (13) 7 (22) 0.32
Abdominal surgery 5 (13) 2 (6) 0.33
Neurological 3 (8) 3 (9) 0.82
Exogenous intoxication 0 2 (6) 0.11
Cardiac 1 (2) 0 0.35
Fentanyl Initial dose (μg/kg/h) 2.15 ± 1.06 2.35 ± 1.21 0.48
Accumulated dose (μg) 40,608 ± 24,882 41,284 ± 20,545 0.90
Midazolam maleate
Accumulated dose (mg) 1,052 ± 820 1,014 ± 672 0.83
Days on fentanyl before start of weaning 10.1 ± 6 10.4 ± 4.4 0.80
MV days before start of weaning 10.6 ± 6.8 10.3 ± 4.5 0.87
ΔT Hosp. X ICU 3 ± 8 4 ± 12 0.88
Data are presented as n (%) or mean ± standard deviation. ΔT Hosp. X ICU = Time from hospital stay until ICU admission. APACHE, acute physiology and chronic
health evaluation; CG, Control group; ICU, intensive care unit; MG, methadone group; MV, mechanical ventilation
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intervention (methadone) and the reason for exclusion
(death or long-term mechanical ventilation need).
Opioid substitution strategies aim to suppress the
opioid withdrawal intolerance that, as demonstrated in
children in the study of Katz et al., is correlated to the
total amount received and the infusion duration. Accu-
mulated doses of 1.5 mg/kg fentanyl or a continuous
infusion over five days is associated with more than a
50% chance of developing a withdrawal syndrome. This
rate increases to 100% at doses of 2.5 mg/kg or an infu-
sion duration of nine days or more [9]. The abrupt
withdrawal of fentanyl may be associated with manifes-
tations of withdrawal that necessitate the administration
of supplemental doses of parenteral opioids, in addition
to sedatives and antipsychotics. Such procedures may
result in respiratory depression or impairment of the
cough reflex, which compromise the safety of extubation
and result in longer MV.
The concern with early ventilation weaning is justified
by the complications associated with extensions in MV
duration, ICU stay and hospital stay [32]. In this con-
text, the substitution of fentanyl with methadone may
be a viable management strategy for ventilation weaning.
Case series and historical control studies in pediatric
intensive care units have suggested a role for methadone
in preventing opioid withdrawal syndrome and acceler-
ating IV opioid weaning [23-27]. We have not found
any study using methadone in adult ICUs.
The replacement of opioid agonists with clonidine is
also effective in the treatment and prevention of with-
drawal symptoms; however, side effects, such as
Hazard Ratio: 2.64; 95% CI: 1.22 - 5.69; p < 0.02 
p = 0,11 
Figure 2 Kaplan-Meier curve of the weaning time from MV. The curve shows the probability of successful weaning (P = 0.11). The difference
was significant until the fifth day (P < 0.02). Dotted line: CG (parenteral fentanyl); continuous line: MG. The numbers on the perpendicular dotted
lines are the median durations of the weaning time in each group. CG, control group; MG, methadone group; MV, mechanical ventilation.
Table 2 Patients who completed weaning.
Patients Total Methadone
Group
Control
Group
Included 68 37 31
Completed weaning 54 29 25
Censored at death 14 08 06
Total death during the study 24 12 12
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bradycardia and hypotension, may limit its use [18,20].
Other strategies, including the use of extremely short
duration opioids (remifentanil) and propofol, have
resulted in a decreased duration of MV and ICU stay
[31,33].
The use of enteral methadone did not reduce the
duration of MV or the ICU or hospital stay, as has been
observed in other strategies for the abbreviation of the
duration of MV using alternative protocols for sedation
and analgesia [12-15]. Several factors may have contrib-
uted to this result. First, our sample was calculated to
evaluate the length of MV weaning. Possibly, a study
with a larger sample size and a different design might
better assess the impact of this strategy on the duration
of MV, ICU stay and hospital stay.
Our study had some other limitations. The randomiza-
tion was performed by a simple lottery system. Perhaps we
should have used a block randomization scheme. The pro-
longed phase of patient enrollment may have generated
bias. The difficulty in recognizing and distinguishing
symptoms of withdrawal from expressions of pain is also
potentially significant in this study. All adrenergic manifes-
tations were treated with a bolus of fentanyl, and at the
discretion of the ICU doctor, a bolus of midazolam was
also added. Unfortunately, we have not collected data on
the dose of other sedatives, analgesics and antipsychotics.
Conclusions
The results of this study suggest that the introduction of
enteral methadone during the weaning process from
Hazard Ratio: 2,06 (IC 95% 1,17 a 3,63; p < 0,004)  
Figure 3 Kaplan-Meier curve of the weaning time from MV among the 54 patients who were successfully weaned. The curve shows the
probability of successful weaning from MV (P < 0.004). Dotted line: CG (parenteral fentanyl); continuous line: MG. The numbers on the
perpendicular dotted lines are the median durations of the weaning time in each group. CG, control group; MG, methadone group; MV,
mechanical ventilation.
Wanzuita et al. Critical Care 2012, 16:R49
http://ccforum.com/content/16/2/R49
Page 7 of 9
sedation and analgesia for mechanically ventilated
patients may abbreviate the duration of weaning from
MV. We believe these results need confirmation by lar-
ger randomized trials before being considered for clini-
cal practice.
Key messages
• Abrupt interruption of IV opioids after more than
five days of continuous infusion may lead to with-
drawal manifestations; however, gradual tapering of
fentanyl may delay extubation.
• Replacement of fentanyl by enteral methadone in
critically ill adult patients who were on fentanyl infu-
sion for more than five days may abbreviate weaning
from mechanical ventilation without increasing with-
drawal manifestations.
• Larger randomized controlled trials are required to
confirm these observations.
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